The pharmacokinetics of isoxicam in elderly patients with rheumatoid arthritis.

Abstract

Nineteen patients, aged 60 years and over, with rheumatoid arthritis participated in a clinical trial to investigate the pharmacokinetics of isoxicam (a new non-steroidal anti-inflammatory drug) in this age group. The purpose of the study was to determine if the pharmacokinetics are different compared to a younger healthy population. The half-lives were independent of dosage, indicating linearity of pharmacokinetics. Furthermore, the half-lives after repeated dosing were not different from those found after single doses of 400 mg. This shows that there is neither undue accumulation of the drug nor induction of its own metabolism. These results are similar to the results obtained in other centres when isoxicam was administered to healthy subjects between 18 and 32 years.

• Authors: E M Grace, J M Rosenfeld, G D Sweeney, W W Buchanan
• Journal: Current medical research and opinion (Curr Med Res Opin) Vol. 10 Issue 9 Pg. 580-91 ( 1987) ISSN: 0300-7995 [Print] England
• PMID: 3436154 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Piroxicam
• isoxicam

Topics

• Aged
• Anti-Inflammatory Agents, Non-Steroidal (adverse effects, pharmacokinetics)
• Arthritis, Rheumatoid (blood, drug therapy)
• Female
• Half-Life
• Humans
• Male
• Middle Aged
• Piroxicam (adverse effects, analogs & derivatives, pharmacokinetics, therapeutic use)